The Global Health Body Issues Concern Over Acute Scarcity of Obesity Jabs

Less than 10% of patients that would benefit from GLP-1 drugs such as Wegovy are able to get them, caution the WHO as it issues its inaugural guidance on the medications.

Considering over a billion individuals worldwide currently living with obesity, it is calling for more widespread and fairer availability to these injectable treatments.

Per projections, over two billion are projected to be obese by 2030 unless action is taken.

"Our latest guidance affirms that obesity is a chronic disease that can be managed with comprehensive and continuous treatment," remarked its chief Tedros Adhanom Ghebreyesus.

Substantial prices, limited production capacity, and logistical bottlenecks are major obstacles to widespread availability to the injections that can aid individuals in losing considerable body mass, explains the agency.

Weight-Loss Drug Supply Crisis

Despite the present most favorable case, the supply of such drugs would only suffice for about 100 million people – fewer than 10% of those who need them, according to the health organization.

The guideline encourages nations and manufacturers to widen availability, through measures including voluntary licensing.

Exclusive production rights on semaglutide – the main component of a leading brand – is set to lapse in a number of countries in 2026.

The Way Obesity Drugs Operate

These medications replicate a biological compound to slow digestion, reduce hunger and boost the sense of being full so users consume fewer calories.

People commonly start to lose weight within a few weeks of beginning the regular doses.

Evidence points to people may put most of the weight back on within a year of discontinuing the treatment, when their normal appetite come back.

To be carrying excess weight raises your risk for contracting diseases, such as type 2 diabetes, heart disease, stroke, and certain malignancies.

Excess weight impacts people in every country and was responsible for millions of fatalities worldwide in 2024, as per the health agency.